// App-Quantinova.ai

2839 : Phase II Study of Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy As Consolidation and Maintenance Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Following Chemotherapy-Sparing Induction

Researchers

Presenter

  • Mark B. Geyer

Principal Investigators

  • Amber C. King

  • Justin C. O'Brien

  • Jae H. Park

Medical Centers

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY

  • Department of Surgery, Gynecologic Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Hematocrit

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

  • Methotrexate

  • Hydroxyurea

  • Hydroxycarbamide

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • NCT04329325

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved